Enzo Biochem (ENZ) 10-Q 16 Mar 21 2021 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jan. 31, 2021	Mar. 08, 2021
Document Information Line Items
Entity Registrant Name	ENZO BIOCHEM INC
Document Type	10-Q
Current Fiscal Year End Date	--07-31
Entity Common Stock, Shares Outstanding		48,228,567
Amendment Flag	false
Entity Central Index Key	0000316253
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jan. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity File Number	001-09974
Entity Incorporation, State or Country Code	NY
Entity Interactive Data Current	Yes

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jan. 31, 2021	Jul. 31, 2020
Current assets:
Cash and cash equivalents	$ 44,536	$ 47,865
Accounts receivable, net	12,095	9,141
Inventories	9,258	7,784
Prepaid expenses	3,994	3,975
Total current assets	69,883	68,765
Property, plant, and equipment, net	14,463	14,482
Right-of-use assets	18,459	19,916
Goodwill	7,452	7,452
Intangible assets, net	393	538
Other, including restricted cash of $750	1,381	1,385
Total assets	112,031	112,538
Current liabilities:
Accounts payable - trade	4,432	8,503
Accrued liabilities	14,589	12,833
Current portion of operating lease liabilities	3,680	4,121
Other current liabilities and finance leases short term	248	344
Other short term debt	7,000	7,000
Total current liabilities	29,949	32,801
Other liabilities and finance leases long term	155	192
Operating lease liabilities, non-current	15,710	16,679
Long term debt - net	4,428	4,485
Total liabilities	50,242	54,157
Commitments and contingencies – see Note 12
Stockholders’ equity:
Preferred Stock, $.01 par value; authorized 25,000,000 shares; no shares issued or outstanding
Common Stock, $.01 par value; authorized 75,000,000 shares; shares issued and outstanding: 48,227,750 at January 31, 2021 and 47,895,050 at July 31, 2020	482	479
Additional paid-in capital	335,688	334,473
Accumulated deficit	(275,651)	(278,252)
Accumulated other comprehensive income	1,270	1,681
Total stockholders’ equity	61,789	58,381
Total liabilities and stockholders’ equity	$ 112,031	$ 112,538

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Thousands	Jan. 31, 2021	Jul. 31, 2020
Statement of Financial Position [Abstract]
Other, including restricted cash (in Dollars)	$ 750	$ 750
Preferred stock par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	48,227,750	47,895,050
Common stock, shares outstanding	48,227,750	47,895,050

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2021	Jan. 31, 2020
Income Statement [Abstract]
Revenues	$ 31,466	$ 19,384	$ 60,121	$ 39,591
Operating costs and expenses:
Cost of revenues	15,645	13,575	32,403	28,096
Research and development	806	1,065	1,552	2,119
Selling, general and administrative	11,013	10,693	21,027	21,832
Legal and related expense	2,292	2,060	2,932	3,756
Total operating costs and expenses	29,756	27,393	57,914	55,803
Operating income (loss)	1,710	(8,009)	2,207	(16,212)
Other income (expense):
Interest, net	(49)	171	(100)	408
Other	16	72	33	199
Foreign exchange gain	625	79	461	270
Total other income (expense)	592	322	394	877
Income (loss) before income taxes	2,302	(7,687)	2,601	(15,335)
Income taxes
Net income (loss)	$ 2,302	$ (7,687)	$ 2,601	$ (15,335)
Net income (loss) per common share:
Basic (in Dollars per share)	$ 0.05	$ (0.16)	$ 0.05	$ (0.32)
Diluted (in Dollars per share)	$ 0.05	$ (0.16)	$ 0.05	$ (0.32)
Weighted average common shares outstanding:
Basic (in Shares)	48,006	47,557	47,951	47,557
Diluted (in Shares)	48,053	47,557	47,973	47,557

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2021	Jan. 31, 2020
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 2,302	$ (7,687)	$ 2,601	$ (15,335)
Other comprehensive loss:
Foreign currency translation adjustments	(582)	(83)	(411)	(354)
Comprehensive income (loss)	$ 1,720	$ (7,770)	$ 2,190	$ (15,689)

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Total
Balance at Jul. 31, 2019	$ 476	$ 332,704	$ (249,732)	$ 2,580	$ 86,028
Balance (in Shares) at Jul. 31, 2019	47,556,807
Net income (loss)			(15,335)		(15,335)
Share-based compensation charges		521			521
Vesting of restricted stock
Vesting of restricted stock (in Shares)	811
Foreign currency translation adjustments				(354)	(354)
Balance at Jan. 31, 2020	$ 476	333,225	(265,067)	2,226	70,860
Balance (in Shares) at Jan. 31, 2020	47,557,618
Balance at Oct. 31, 2019	$ 476	332,923	(257,380)	2,309	78,328
Balance (in Shares) at Oct. 31, 2019	47,556,807
Net income (loss)			(7,687)		(7,687)
Share-based compensation charges		302			302
Vesting of restricted stock
Vesting of restricted stock (in Shares)	811
Foreign currency translation adjustments				(83)	(83)
Balance at Jan. 31, 2020	$ 476	333,225	(265,067)	2,226	70,860
Balance (in Shares) at Jan. 31, 2020	47,557,618
Balance at Jul. 31, 2020	$ 479	334,473	(278,252)	1,681	58,381
Balance (in Shares) at Jul. 31, 2020	47,895,050
Net income (loss)			2,601		2,601
Share-based compensation charges		343			343
Issuance of common stock for bonus payments	$ 3	872			875
Issuance of common stock for bonus payments (in Shares)	332,700
Foreign currency translation adjustments				(411)	(411)
Balance at Jan. 31, 2021	$ 482	335,688	(275,651)	1,270	61,789
Balance (in Shares) at Jan. 31, 2021	48,227,750
Balance at Oct. 31, 2020	$ 479	334,640	(277,953)	1,852	59,018
Balance (in Shares) at Oct. 31, 2020	47,895,050
Net income (loss)			2,302		2,302
Share-based compensation charges		176			176
Issuance of common stock for bonus payments	$ 3	872			875
Issuance of common stock for bonus payments (in Shares)	332,700
Foreign currency translation adjustments				(582)	(582)
Balance at Jan. 31, 2021	$ 482	$ 335,688	$ (275,651)	$ 1,270	$ 61,789
Balance (in Shares) at Jan. 31, 2021	48,227,750

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	6 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Cash flows from operating activities:
Net income (loss)	$ 2,601	$ (15,335)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization of property, plant and equipment	1,144	1,142
Amortization of intangible assets	151	292
Share-based compensation charges	343	521
Accrual for share-based 401(k) employer match expense	423	413
Foreign exchange (gain)	(504)	(319)
Changes in operating assets and liabilities:
Accounts receivable	(2,892)	1,848
Inventories	(1,392)	368
Prepaid expenses and other assets	(62)	98
Accounts payable – trade	(4,062)	877
Accrued liabilities, other current liabilities and other liabilities	2,222	2,104
Total adjustments	(4,629)	7,344
Net cash used in operating activities	(2,028)	(7,991)
Cash flows from investing activities:
Capital expenditures	(1,123)	(434)
Net cash used in investing activities	(1,123)	(434)
Cash flows from financing activities:
Repayments under mortgage agreement and finance leases	(207)	(229)
Net cash used in financing activities	(207)	(229)
Effect of exchange rate changes on cash and cash equivalents	29	10
Decrease in cash and cash equivalents and restricted cash	(3,329)	(8,644)
Cash and cash equivalents and restricted cash - beginning of period	48,615	60,896
Total cash and cash equivalents and restricted cash - end of period	45,286	52,252
The composition of total cash and cash equivalents and restricted cash is as follows:
Cash and cash equivalents	44,536	51,502
Restricted cash included in other assets	750	750
Total cash and cash equivalents and restricted cash	$ 45,286	$ 52,252

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jan. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Note 1 – Basis of Presentation The accompanying consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Enzo Clinical Labs, Enzo Therapeutics, Enzo Realty LLC and Enzo Realty II LLC, collectively or with one or more of its subsidiaries referred to as the “Company” or “Companies”. The Company has three reportable segments: Clinical Services, Products, and Therapeutics. The consolidated balance sheet as of January 31, 2021, the consolidated statements of operations, comprehensive income (loss) and stockholders’ equity for the three and six months ended January 31, 2021, and the consolidated statements of cash flows for the six months ended January 31, 2021 (the “interim statements”) are unaudited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted. The interim statements should be read in conjunction with the consolidated financial statements for the fiscal year ended July 31, 2020 and notes thereto contained in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2020 has been derived from the audited financial statements at that date. The results of operations for the six months ended January 31, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2021. A novel strain of coronavirus (“COVID-19”) continues to spread and severely impact the economy of the United States and other countries around the world. Federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19 have resulted in, among other things, a significant reduction in physician office visits, the cancellation of elective medical procedures, customers of our products closing or severely curtailing their operations (voluntarily or in response to government orders), and the adoption of work-from-home or shelter-in-place policies. The COVID-19 impact on the Company’s operations is consistent with the overall industry and publicly issued statements from competitors, partners, and vendors. The extent to which our businesses may be affected by the COVID-19 pandemic will largely depend on both current and future developments, including its duration, spread and the emergence of variants, its treatment with authorized vaccines and vaccines in various stages of development and federal approval, and related work and travel advisories and restrictions, all of which are highly uncertain and cannot be reasonably predicted at this time. Global supply chain issues due to the pandemic hamper both the manufacturing of products within the life science division as well as testing capabilities in the clinical laboratory. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. The extent to which the COVID-19 pandemic impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the COVID-19 pandemic, the extent to which it will impact worldwide macroeconomic conditions including, but not limited to, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of January 31, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s patient self-pay revenue concessions and credit losses in the Clinical Services segment, accounts receivable, inventories and the carrying value of goodwill and other long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods. Effect of New Accounting Pronouncements Pronouncements Issued but Not Yet Adopted In June 2016, FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326) In December 2019, the FASB issued ASU No. 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations. Concentration Risk Other than the Medicare program, two providers whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represent approximately 35% and 34% of Clinical Services net revenue for the three and six month periods ended January 31, 2021. These two providers represent approximately 33% of Clinical Services net revenue for each of the three and six month periods ended January 31, 2020 Income Taxes The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance where it is not more likely than not the benefits will be realized in the foreseeable future. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. It is the Company’s policy to provide for uncertain tax positions, if any, and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. To the extent the Company prevails in matters for which a liability for an unrecognized tax benefit is established or is required to pay amounts in excess of the liability, the Company’s effective tax rate in a given financial statement period may be affected. We maintain a full valuation allowance on all tax assets and, as a consequence, do not provide any tax benefit for the fiscal 2020 period loss or tax provision for the fiscal 2021 period pre-tax income. Fair Value Measurements The Company determines fair value measurements used in its consolidated financial statements based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs, as determined by either the principal market or the most advantageous market. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy. The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest. Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable.

Net income (loss) per share

Net income (loss) per share	6 Months Ended
	Jan. 31, 2021
Earnings Per Share [Abstract]
Net income (loss) per share	Note 2 – Net income (loss) per share Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. For the three and six months ended January 31, 2021, approximately 47,000 and 23,000 weighted average stock options respectively were included in the calculation of diluted weighted average shares outstanding. As a result of the net loss for the three and six months ended January 31, 2020, diluted weighted average shares outstanding are the same as basic weighted average shares outstanding, and do not include the potential common shares from stock options, unearned performance stock units and unvested restricted stock because to do so would be antidilutive. For the three and six months ended January 31, 2020, approximately zero and 64,000 of potential common shares (“in the money options”) and unvested restricted stock respectively, were excluded from the calculation of diluted earnings per share. For the three and six months ended January 31, 2021, the effect of approximately 2,264,000 and 2,122,000 of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income per share because their effect would be anti-dilutive. For the three and six months ended January 31, 2020, the effect of approximately 1,897,000 and 1,606,000 of outstanding “out of the money” options to purchase common shares were excluded from the calculation of diluted net income per share because their effect would be anti-dilutive.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jan. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Note 3 – Revenue Recognition Clinical Services Revenue Service revenues in the Company’s clinical services business accounted for approximately 75% and 64% of the Company’s total revenues for the six months ended January 31, 2021 and 2020, and are primarily comprised of a high volume of relatively low-dollar transactions. The services business, which provides clinical testing services, satisfies its performance obligation and recognizes revenues upon completion of the testing process for a specific patient and reporting to the ordering physician. The Company may also perform clinical testing services for other laboratories and will recognize revenue from those services when reported to the ordering laboratory. The Company estimates the amount of consideration it expects to receive from customer groups using the portfolio approach. These estimates of the expected consideration include the impact of contractual allowances and price concessions on our customer group portfolios consisting of healthcare insurers, government payers, client payers and patients as described below. Contracts with customers in our laboratory services business do not contain a financing component, based on the typically limited period of time between performance of services and collection of consideration. The transaction price includes variable consideration in the form of the contractual allowance and price concessions as well as the collectability of the transaction based on patient intent and ability to pay. The Company uses the expected value method in estimating the amount of the variability included in the transaction price. The following are descriptions of our laboratory services business portfolios: Third party payers and Health Maintenance Organizations (HMO’s) Reimbursements from third party payers, primarily healthcare insurers and HMO’s are based on negotiated fee-for-service schedules and on capitated payment rates. Revenues consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from such payers, which considers historical collection and denial experience and the terms of the Company’s contractual arrangements. Adjustments to the allowances, based on actual receipts from the third-party payers, are recorded upon settlement. Collection of the consideration the Company expects to receive is normally a function of providing complete and correct billing information to these third party payers within the various filing deadlines, and typically occurs within 30 to 90 days of billing. Provided the Company has billed healthcare insurers accurately with complete information prior to the established filing deadline, there has historically been little to no collection risk. If there has been a delay in billing, the Company determines if the amounts in question will likely go past the filing deadline, and if so, will reserve accordingly for the billing. Third-party payers, including government programs, may decide to deny payment or recoup payments for testing that they contend was improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received. Our revenues may be subject to adjustment as a result of these factors among others, including without limitation, differing interpretations of billing and coding guidance and changes by government agencies and payers in interpretations, requirements, and “conditions of participation” in various programs. Government Payer - Medicare Reimbursements from Medicare are based on fee-for-service schedules set by Medicare, which is funded by the government. Revenues consist of amounts billed net of contractual allowances for differences between amounts billed and the estimated consideration the Company expects to receive from Medicare, which considers historical collection and denial experience and other factors. Adjustments to the allowances, based on actual receipts from the government payers, are recorded upon settlement. Collection of consideration the Company expects to receive is normally a function of providing the complete and correct billing information within the various filing deadlines and typically occurs within 60 days of billing. Provided the Company has billed the government payer accurately with complete information prior to the established filing deadline, there has historically been little to no collection risk. If there has been a delay in billing, the Company determines if the amounts in question will likely go past the filing deadline, and, if so, it will reserve accordingly for the billing. Patient self pay Uninsured patients are billed based on established patient fee schedules or fees negotiated with physicians on behalf of their patients. Coinsurance and deductible responsibilities based on fees negotiated with healthcare insurers are also billed to insured patients and included in this portfolio. Collection of billings from patients is subject to credit risk and ability of the patients to pay. Revenues consist of amounts billed net of discounts provided to uninsured patients in accordance with the Company’s policies and implicit price concessions. Implicit price concessions represent differences between amounts billed and the estimated consideration the Company expects to receive from patients, which considers historical collection experience and other factors including current market conditions. Adjustments to the estimated allowances, based on actual receipts from the patients, are recorded upon settlement. Patient responsibility is invoiced and if it reaches 91 days outstanding, the account is sent to a collection agency for further processing. After the account has been with the collection agency for at least 105 days, and is determined to be uncollectable it is written off. The following table represents clinical services net revenues and percentages by type of customer: Three months ended Three months ended Revenue category Third-party payer $ 15,023 63 % $ 6,404 51 % Medicare 3,910 16 3,025 24 Patient self-pay 1,997 8 1,447 12 HMO’s 3,058 13 1,637 13 Total $ 23,988 100 % $ 12,513 100 % Six months ended Six months ended Revenue category Third-party payer $ 27,503 61 % $ 12,796 51 % Medicare 7,313 16 6,178 24 Patient self-pay 4,556 10 2,966 12 HMO’s 5,839 13 3,353 13 Total $ 45,211 100 % $ 25,293 100 % For six months ended January 31, 2021 and 2020, all of the Company’s clinical services revenues were generated within the United States. Products Revenue Products revenues consist of the sale of single-use products used in the identification of genomic information and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Payment terms for shipments to end-user and distributor customers may range from 30 to 90 days. Any claims for credit or return of goods may be made generally within 30 days of receipt. Revenues are reduced to reflect estimated credits and returns, although historically these adjustments have not been material. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. Products revenue by geography is as follows: Three Months Ended January 31 Six Months Ended January 31 2021 2020 2021 2020 United States $ 3,524 $ 3,807 $ 7,469 $ 8,331 Europe 2,635 2,066 5,066 3,975 Asia Pacific 1,319 998 2,375 1,992 Products revenue $ 7,478 $ 6,871 $ 14,910 $ 14,298

Supplemental Disclosure for Sta

Supplemental Disclosure for Statement of Cash Flows	6 Months Ended
	Jan. 31, 2021
Supplemental Cash Flow Elements [Abstract]
Supplemental disclosure for statement of cash flows	Note 4 - Supplemental disclosure for statement of cash flows In the six months ended January 31, 2021 and 2020, interest paid by the Company was $123 and $136, respectively. For the six months ended January 31, 2021 and 2020, the net reductions in the measurement of right of use assets and liabilities included in cash flows from operating activities was $48 and $91, respectively. The changes are included in changes in accrued liabilities, other current liabilities, and other liabilities in the statement of cash flows. In January 2021, the Company issued 332,700 shares of common stock to two senior executives in settlement of their accrued bonuses totaling $875.

Inventories

Inventories	6 Months Ended
	Jan. 31, 2021
Inventory Disclosure [Abstract]
Inventories	Note 5 – Inventories Inventories consist of the following at January 31: January 31, July 31, Raw materials $ 1,266 $ 1,019 Work in process 2,561 2,587 Finished products 5,431 4,178 $ 9,258 $ 7,784

Goodwill and intangible assets

Goodwill and intangible assets	6 Months Ended
	Jan. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and intangible assets	Note 6 – Goodwill and intangible assets Goodwill The Company’s net carrying amount of goodwill is in the Clinical Laboratory Services segment and is $7,452 as of January 31, 2021 and 2020. Intangible assets The Company’s change in the net carrying amount of intangible assets, all in the Life Sciences Products segment is as follows: Gross Accumulated Amortization Net July 31, 2020 $ 27,686 $ (27,148 ) $ 538 Amortization expense - (151 ) (151 ) Foreign currency translation 168 (162 ) 6 January 31, 2021 $ 27,854 $ (27,461 ) $ 393 Intangible assets, all finite-lived, consist of the following: January 31, 2021 July 31, 2020 Gross Accumulated Net Gross Accumulated Net Patents $ 11,027 $ (11,023 ) $ 4 $ 11,027 (11,014 ) $ 13 Customer relationships 12,095 (11,706 ) 389 12,003 (11,478 ) 525 Website and acquired content 1,028 (1,028 ) - 1,022 (1,022 ) - Licensed technology and other 492 (492 ) - 483 (483 ) - Trademarks 3,212 (3,212 ) - 3,151 (3,151 ) - Total $ 27,854 $ (27,461 ) $ 393 $ 27,686 (27,148 ) $ 538 At January 31, 2021, information with respect to acquired intangibles is as follows: Useful life assigned Weighted average Customer relationships 8 -15 years 1 year At January 31, 2021, the weighted average remaining useful life of all intangible assets was approximately two years.

Long term debt

Long term debt	6 Months Ended
	Jan. 31, 2021
Debt Disclosure [Abstract]
Long term debt	Note 7 – Long term debt In connection with the purchase of our new facility in November 2018, a wholly-owned subsidiary (the “mortgagor subsidiary”) of the Company entered into a Fee Mortgage and Security Agreement (the “mortgage agreement”) with Citibank, N.A. (the “mortgagee”). The mortgage agreement provides for a loan of $4,500 for a term of 10 years, bears a fixed interest rate of 5.09% per annum and requires monthly mortgage payments of principal and interest of $30. Debt issuance costs of $72 are being amortized over the life of the mortgage agreement. The balance of unamortized debt issuance cost was $57 at January 31, 2021. At January 31, 2021, the balance owed by the subsidiary under the mortgage agreement was $4.2 million. The Company’s obligations under the mortgage agreement are secured by the new facility and by a $750 cash collateral deposit with the mortgagee as additional security. This restricted cash is included in other assets as of January 31, 2021. We assumed from the seller an operating lease for a tenant at the facility which expired on June 30, 2020. Rental income from the assumed lease for the three and six months ended January 31, 2020 is included in Other income. The mortgage agreement includes affirmative and negative covenants and events of default, as defined. Events of default include non-payment of principal and interest on debt outstanding, non-performance of covenants, material changes in business, breach of representations, bankruptcy or insolvency, and changes in control. The mortgage includes certain financial and liquidity covenants. As of January 31, 2021, the Company was in compliance with those covenants. The liquidity covenant requires that we own and maintain at all times and throughout the remaining term of the loan at least $25 million of liquid assets, defined as time deposits, money market accounts, commercial paper and obligations issued by the U.S. government or any of its agencies. In April 2020, our subsidiary in Switzerland received a loan of CHF 0.4 million ($0.4 million, based on the foreign exchange rate as of January 31, 2021) from the Swiss government under the “Corona Krise” emergency loan program in response to the pandemic. This loan is uncollateralized, bears 0% interest, is due in 5 years, and may be repaid at any time. This loan is included in long term debt – net as of January 31, 2021. The CARES Act expanded the U.S. Small Business Administration’s (SBA) business loan program to create the Paycheck Protection Program (PPP), which provides employers with uncollateralized loans whose primary purpose is to retain or maintain workforce and salaries for a twenty four week period (“covered period”) following receipt of the loan. Currently, PPP loans have a 1% fixed interest rate and are due from two to five years. The primary features of the PPP loan program are to provide funding to companies to cover eligible expenses, and the potential for forgiveness of that portion of the loan spent on payroll and other permitted operating expenses during the covered period, subject to reductions if the borrower fails to maintain or restore employee and salary levels. We applied for the PPP loan based on the eligibility and need requirements established when the program was announced and in April 2020 received $7,000 through Citibank N.A., the Company’s existing lender, pursuant to the PPP (the “PPP Loan”). The PPP Loan matures on April 17, 2022 (the “Maturity Date”), accrues interest at 1% per annum and may be prepaid in whole or in part without penalty. No interest payments are due within the initial six months of the PPP Loan. Interest accrued during the initial six-month period is due and payable, together with the principal, on the Maturity Date. The Company used all proceeds from the PPP Loan to retain employees, maintain payroll and make lease and utility payments to support business continuity throughout the COVID-19 pandemic. All or a portion of the PPP Loan, including interest, could be forgiven by the SBA by applying for forgiveness and providing acceptable documentation that demonstrates the funds were used as required by the terms of forgiveness and in accordance with the SBA’s requirements. Due to complexities with respect to loan forgiveness calculations and government pronouncements with respect to expenditure eligibility, we did not recognize any loan forgiveness as of January 31, 2021 and have classified the loan as other short term debt as we expect to earn loan forgiveness on most, if not all of the loan in less than a year, and have accrued no interest. The SBA intends to audit loans in excess of $2.0 million. The SBA also has announced its intention to require businesses that received loans in excess of $2 million to complete a loan necessity questionnaire to evaluate the good faith certification made on their PPP applications that economic uncertainty made their loan request necessary to support ongoing operations. No assurance can be given that we will obtain forgiveness of the PPP loan in whole or in part. We expect to apply for PPP loan forgiveness with the SBA through our intermediary lending bank in March 2021. Minimum future annual principal payments under these agreements as of January 31, 2021 are as follows: July 31, Total 2021 $ 7,074 2022 152 2023 160 2024 167 2025 604 Thereafter 3,476 Total principal payments 11,633 Less: current portion, included in other current liabilities and other short term debt (7,148 ) Unamortized mortgage cost (57 ) Long term debt - net $ 4,428

Leases

Leases	6 Months Ended
	Jan. 31, 2021
Leases Disclosure [Abstract]
Leases	Note 8 - Leases The Company adopted ASU No. 2016-02 “Leases (Topic 842)”, which requires leases with durations greater than twelve months to be recognized on the balance sheet, using the modified retrospective approach as of August 1, 2019. The Company determines if an arrangement is or contains a lease at contract inception. The Company leases buildings, office space, patient service centers, and equipment primarily through operating leases, and equipment through a limited number of finance leases. Generally, a right-of-use asset, representing the right to use the underlying asset during the lease term, and a lease liability, representing the payment obligation arising from the lease, are recognized on the balance sheet at lease commencement based on the present value of the payment obligation. For operating leases, expense is recognized on a straight-line basis over the lease term. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the right-of-use asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company primarily uses its incremental borrowing rate in determining the present value of lease payments as the Company’s leases generally do not provide an implicit rate. The Company has lease agreements with (i) right-of-use asset payments and (ii) non-lease components (i.e. payments related to maintenance fees, utilities, etc.), which have generally been combined and accounted for as a single lease component. The Company’s leases have remaining terms of less than 1 year to 8 years, some of which include options to extend the leases for up to 5 years. The Company’s lease terms may include renewal options that are reasonably certain to be exercised and termination options that are reasonably certain not to be exercised. Certain of the Company’s lease agreements include rental payments adjusted periodically for inflation or a market rate which are included in the lease liabilities. Leases Balance Sheet Classification January 31, 2021 Assets Operating Right-of-use assets $ 18,459 Finance Property, plant and equipment, net (a) 286 Total lease assets $ 18,745 Liabilities Current: Operating Current portion of operating lease liabilities $ 3,680 Finance Finance leases short term 66 Non-current: Operating Operating lease liabilities, non-current 15,710 Finance Other liabilities and finance leases long term 155 Total lease liabilities $ 19,611 (a) Accumulated amortization of finance lease assets was approximately $1.1 million as of January 31, 2021. Components of lease cost were as follows: Three months ended Six months ended 2021 2020 2021 2020 Operating lease cost $ 1,515 $ 1,474 $ 2,994 $ 2,948 Finance lease cost: Amortization of leased assets 33 60 99 115 Interest on lease liabilities 4 22 9 34 Total lease cost $ 1,552 $ 1,556 $ 3,102 $ 3,097 The maturity of the Company’s lease liabilities as of January 31, 2021 is as follows: Maturity of lease liabilities, years ending July 31, Operating leases Finance leases Total 2021 $ 2,436 $ 44 $ 2,480 2022 4,017 88 4,105 2023 3,318 88 3,406 2024 3,173 22 3,195 2025 3,145 — 3,145 Thereafter 6,370 — 6,370 Total lease payments 22,459 242 22,701 Less: Interest (a) (3,069 ) (21 ) (3,090 ) Present value of lease liabilities $ 19,390 $ 221 $ 19,611 (a) Primarily calculated using the Company’s incremental borrowing rate. Lease term and discount rate for the six months ended January 31, 2021 were as follows: Lease term and discount rate Weighted-average remaining lease term (years): Operating leases 5.9 years Finance leases 2.9 years Weighted-average discount rate: Operating leases 4.95 % Finance leases 9.02 % See Note 4 for cash flow information on cash paid for amounts included in the measurement of lease liabilities for the six months ended January 31, 2021.

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jan. 31, 2021
Payables and Accruals [Abstract]
Accrued Liabilities	Note 9 – Accrued Liabilities At January 31, accrued liabilities consist of: January 31, July 31, Payroll, benefits, and commissions $ 5,601 $ 5,227 Professional fees 704 710 Legal 3,638 2,647 Deferred revenue – CARES Act Advance Payment 2,526 2,526 Other 2,120 1,723 $ 14,589 $ 12,833 Deferred revenue In order to increase cash flow to providers of services and suppliers impacted by the pandemic, the Centers for Medicare and Medicaid Services (CMS) expanded its Accelerated and Advance Payment Program to a broader group of Medicare providers. We applied for and received a $2,526 payment advance from this program in April 2020. The recoupment by CMS of our advance payment had been scheduled to begin 120 days after the date of receipt, at which time every claim we submit from that point would be automatically offset to repay the advance payment. Any unrecouped advance balance remaining after 90 days of the recoupment process was to be repaid such that 210 days after receiving the advance it would be entirely repaid. In October 2020, the Continuing Appropriations Act, 2021 and Other Extensions Act amended the repayment terms of the Advance Payment Program. The recoupment period was extended and the automatic recoupment will begin one year after the date the advance payment was received, which in our case means recoupment will start April 2021. During the first 11 months after recoupment begins, the rate will be 25% of claims processed and repayment will occur through an automatic recoupment of our Medicare payments. We expect the entire balance of the payment advance to be recouped by the end of the 11 month period. If the total amount of the advance payment is not recovered within 29 months from the date the advance was received, a demand letter for the outstanding balance will be issued. Since the Company has the right to repay the advance at any time, the entire balance is considered current. Self-Insured Medical Plan The Company self-funds medical insurance coverage for certain of its U.S. based employees. The risk to the Company is believed to be limited through the use of individual and aggregate stop loss insurance. As of January 31, 2021, the Company has established a reserve of $349, which is included in accrued liabilities, for claims that have been reported but not paid and for claims that have been incurred but not reported. The reserve is based upon the Company’s historical payment trends, claim history and current estimates.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jan. 31, 2021
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Note 10 – Stockholders’ Equity Controlled Equity Offering The Company has a Controlled Equity Offering SM In September 2017, the Company filed with the SEC a “shelf” registration and sales agreement prospectus covering the offering, issuance and sale of our Common Stock that may be issued and sold under the existing Sales Agreement in an aggregate amount of up to $19.2 million. A total of $150 million of securities may be sold under this shelf registration, which was declared effective September 2017. During the six months ended January 31, 2021 and 2020, the Company did not sell any shares of Common Stock under the Sales Agreement. Share-based compensation In January 2011, the Company’s stockholders approved the adoption of the 2011 Incentive Plan (the “2011 Plan”) for the issuance of equity awards, including, among others, options, restricted stock and restricted stock units for up to 3,000,000 shares of common stock. On January 5, 2018, the Company’s stockholders approved the amendment and restatement of the 2011 Plan (the “Amended and Restated 2011 Plan”) to increase the number of shares of common stock available for grant under the 2011 Plan by 2,000,000 shares of common stock bringing the total number of shares available for grant to 5,000,000 shares of common stock. On October 7, 2020, the Company’s Board of Directors approved the amendment and restatement of the Amended and Restated 2011 Plan, with an effective date of October 7, 2020 and subject to approval by the Company’s stockholders at the 2020 annual meeting of stockholders of the Company. The amendment and restatement of the Amended and Restated 2011 Plan was for purposes of, among other things, (i) increasing the shares of common stock available for grant under the Amended and Restated 2011 Plan by an additional 4,000,000 shares of common stock bringing the total number of shares available for grant to 9,000,000 shares of common stock and (ii) extending the term of the Amended and Restated 2011 Plan until October 7, 2030. In January 2021, the Company’s stockholders approved the amendment and restatement of the Amended and Restated 2011 Plan. The exercise price of options granted under the Amended and Restated 2011 Plan, as amended and restated, is equal to or greater than fair market value of the common stock on the date of grant. The Amended and Restated 2011 Plan, as amended and restated, will terminate at the earliest of (a) such time as no shares of common stock remain available for issuance under the plan, (b) termination of the plan by the Company’s Board of Directors, or (c) October 7, 2030. Awards outstanding upon expiration of the Amended and Restated 2011 Plan, as amended and restated, will remain in effect until they have been exercised or terminated, or have expired. As of January 31, 2021, there were approximately 4,623,000 shares of common stock available for grant under the Amended and Restated 2011 Plan, as amended and restated. The amounts of share-based compensation expense recognized in the periods presented are as follows: Three months ended Six months ended 2021 2020 2021 2020 Stock options $ 175 $ 301 $ 341 $ 518 Restricted stock 1 1 2 3 $ 176 $ 302 $ 343 $ 521 The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations: Three months ended Six months ended 2021 2020 2021 2020 Selling, general and administrative $ 162 $ 302 $ 316 $ 521 Cost of revenues 14 - 27 - $ 176 $ 302 $ 343 $ 521 No excess tax benefits were recognized during the six month periods ended January 31, 2021 and 2020. Stock Option Plans The following table summarizes stock option activity during the six month period ended January 31, 2021: Options Weighted Weighted Aggregate Outstanding at July 31, 2020 2,636,496 $ 4.05 Awarded 543,104 $ 2.57 Exercised — $ Expired or forfeited (408,539 ) $ 2.91 Outstanding at end of period 2,771,061 $ 3.80 3.0 years $ 114 Exercisable at end of period 1,566,259 $ 1.9 years $ As of January 31, 2021, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was $1,079 and the weighted average period over which the remaining expense of these awards is expected to be recognized is approximately nineteen months. The intrinsic value of in the money stock option awards at the end of the period represents the Company’s closing stock price on the last trading day of the period in excess of the exercise price multiplied by the number of options. Performance Stock Units To better align the long-term interest of executives with growing U.S. practices, beginning in fiscal 2018, the Company’s board of directors approved long-term incentive awards in the form of performance-based stock units (“Performance Stock Units” or “PSUs”) in addition to time based stock options. The PSUs earned will be determined over a three-year performance period. The primary performance metrics will be revenue and Adjusted EBITDA growth. Payouts based on revenue and adjusted EBITDA goals will be modified based on Total Shareholder Return (“TSR”) performance relative to Enzo’s peer group. During the fiscal years ended 2020, 2019 and 2018, the Company’s board of directors approved the award of PSUs to its executive officers, whose established grant dates are in the table below. These awards provide for the grant of shares of our common stock at the end of a three–year period based on the achievement of average revenue growth and adjusted EBITDA growth over that period. During the six months ended January 31, 2021, one former executive forfeited a total of 6,000 PSUs. During the six months ended January 31, 2020, one former executive forfeited a total of 14,500 PSUs. As of January 31, 2021, the Company did not accrue any compensation expense for the outstanding PSU’s. There were no PSU awards approved by the Company’s board of directors through the six months ended January 31, 2021. The following table summarizes PSU’s granted and outstanding as of January 31, 2021: Grant Date Total Grant Forfeitures Outstanding Fair Market Value At Grant Date (000s) 10/15/2018 32,000 (6,000 ) 26,000 $ 107 10/15/2019 80,500 (14,500 ) 66,000 $ 222 10/19/2020 98,600 - 98,600 $ 207

Segment reporting

Segment reporting	6 Months Ended
	Jan. 31, 2021
Segment Reporting [Abstract]
Segment reporting	Note 11 – Segment reporting The Company has three reportable segments: Products, Clinical Services and Therapeutics. The Company’s Products segment develops, manufactures, and markets products to research and pharmaceutical customers. The Clinical Services segment provides diagnostic services to the health care community. The Company’s Therapeutics segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Other” consist of corporate general and administrative costs which are not allocable to the three reportable segments. All intersegment activities are eliminated. Legal and related expenses incurred to defend the Company’s intellectual property, which may result in settlements recognized in another segment and other general corporate matters are considered a component of the Other segment. Legal and related expenses specific to other segments’ activities are allocated to those segments. Legal settlements, net, represent activities for which royalties would have been received in the Company’s Products segment. Management of the Company assesses assets on a consolidated basis only and therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The following financial information represents the operating results of the reportable segments of the Company: Three months ended January 31, 2021 Clinical Products Therapeutics Other Consolidated Revenues – Services and Products $ 23,988 $ 7,478 - - $ 31,466 Operating costs and expenses: Cost of revenues 11,708 3,937 - - 15,645 Research and development 160 633 $ 13 - 806 Selling, general and administrative 6,425 2,593 16 $ 1,979 11,013 Legal and related expenses 71 1 - 2,220 2,292 Total operating costs and expenses 18,364 7,164 29 4,199 29,756 Operating income (loss) 5,624 314 (29 ) (4,199 ) 1,710 Other income (expense): Interest (4 ) 8 - (53 ) (49 ) Other 14 2 - - 16 Foreign exchange gain - 625 - - 625 Net income (loss) $ 5,634 $ 949 $ (29 ) $ (4,252 ) $ 2,302 Depreciation and amortization included above $ 381 $ 188 $ - $ 66 $ 635 Share-based compensation included in above: Selling, general and administrative 10 16 - 136 162 Cost of revenues 14 - - - 14 Total $ 24 $ 16 $ - $ 136 $ 176 Capital expenditures $ 341 $ 154 $ - $ 11 $ 506 Three months ended January 31, 2020 Clinical Products Therapeutics Other Consolidated Revenues $ 12,513 $ 6,871 - - $ 19,384 Operating costs and expenses: Cost of revenues 10,243 3,332 - - 13,575 Research and development 373 503 189 - 1,065 Selling, general and administrative 5,895 2,530 - 2,268 10,693 Legal fee expense 38 1 - 2,021 2,060 Total operating costs and expenses 16,549 6,366 189 4,289 27,393 Operating income (loss) (4,036 ) 505 (189 ) (4,289 ) (8,009 ) Other income (expense): Interest (10 ) 16 - 165 171 Other 16 7 - 49 72 Foreign exchange gain - 79 - - 79 Net (loss) income $ (4,030 ) 607 (189 ) (4,075 ) (7,687 ) Depreciation and amortization included above $ 392 253 - 65 710 Share-based compensation included in above: Selling, general and administrative 33 22 - 247 302 Total $ 33 22 - 247 302 Capital expenditures $ 142 18 - - 160 Six months ended January 31, 2021 Clinical Products Therapeutics Other Consolidated Revenues – Services and Products $ 45,211 $ 14,910 - - $ 60,121 Operating costs and expenses: Cost of revenues 24,703 7,700 - - 32,403 Research and development 281 1,225 $ 46 - 1,552 Selling, general and administrative 12,523 5,038 33 $ 3,433 21,027 Legal and related expenses 96 6 - 2,830 2,932 Total operating costs and expenses 37,603 13,969 79 6,263 57,914 Operating income (loss) 7,608 941 (79 ) (6,263 ) 2,207 Other income (expense): Interest (10 ) 18 - (108 ) (100 ) Other 29 4 - - 33 Foreign exchange gain 461 - - 461 Net income (loss) $ 7,627 $ 1,424 $ (79 ) $ (6,371 ) $ 2,601 Depreciation and amortization included above $ 790 $ 373 $ - $ 132 $ 1,295 Share-based compensation included in above: Selling, general and administrative 19 32 - 265 316 Cost of revenues 27 - - - 27 Total $ 46 $ 32 $ - $ 265 $ 343 Capital expenditures $ 881 $ 198 $ - $ 44 $ 1,123 Six months ended January 31, 2020 Clinical Products Therapeutics Other Consolidated Revenues – Services and Products $ 25,293 $ 14,298 - - $ 39,591 Operating costs and expenses: Cost of revenues 21,218 6,878 - - 28,096 Research and development 723 1,019 $ 377 - 2,119 Selling, general and administrative 12,110 5,287 - $ 4,435 21,832 Legal and related expenses 88 1 - 3,667 3,756 Total operating costs and expenses 34,139 13,185 377 8,102 55,803 Operating income (loss) (8,846 ) 1,113 (377 ) (8,102 ) (16,212 ) Other income (expense): Interest (22 ) 34 - 396 408 Other 19 (5 ) - 185 199 Foreign exchange gain - 270 - - 270 Net income (loss) $ (8,849 ) $ 1,412 $ (377 ) $ (7,521 ) $ (15,335 ) Depreciation and amortization included above $ 801 $ 503 $ - $ 130 $ 1,434 Share-based compensation included in above: Selling, general and administrative. 67 44 - 410 521 Total $ 67 $ 44 $ - $ 410 $ 521 Capital expenditures $ 289 $ 145 $ - $ - $ 434

Contingencies

Contingencies	6 Months Ended
	Jan. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Note 12 Contingencies The Company has brought cases in the United States District Court for the District of Delaware (“the Court”), alleging patent infringement against various companies. In 2017, the Court ruled that the asserted claims of the ‘180 and ‘405 Patents are invalid for nonenablement in cases involving Abbott, Becton Dickinson, Gen-Probe, Hologic, and Roche. That ruling was affirmed by the United States Court of Appeals for the Federal Circuit (“Federal Circuit”) in June 2019. Enzo subsequently filed a petition for certiorari regarding the invalidity ruling for the ‘180 and ‘405 Patents in February 2020; the Supreme Court denied Enzo’s petition on March 30, 2020. There are currently two cases that were originally brought by the Company in the Court. In those two cases, Enzo alleges patent infringement against Becton Dickinson Defendants and Roche Defendants, respectively. The claims in those cases involve the ‘197 Patent. Both cases are stayed. In separate inter partes review proceedings before the U.S. Patent and Trademark Office involving, among others, Becton Dickinson, certain claims of the ‘197 Patent were found unpatentable as anticipated or obvious and cancelled by the Patent Trial and Appeals Board (“Board”). Enzo appealed that decision to the Federal Circuit. On August 16, 2019, the Federal Circuit affirmed the Board’s decision, finding that each of the challenged claims is unpatentable. The Company filed a petition for rehearing and rehearing en banc on October 30, 2019, which the Federal Circuit denied on December 4, 2019. The Company filed a petition for certiorari with the Supreme Court on March 3, 2020, which was denied. In April 2019, the Company entered into an agreement with Hologic and Grifols, resolving litigation resulting from four cases originally brought by the Company in the Court. As a result, Enzo dismissed (1) a stayed patent litigation regarding the ’180 and ’197 Patent against Hologic in the Court; (2) the Consolidated Appeals against Gen-Probe and Hologic resulting from two cases filed in the Court, and (3) the Company’s appeal in the litigation involving the ’581 Patent that involved both Hologic and Grifols. As a result of the agreement with Hologic, Hologic withdrew from Enzo’s Federal Circuit appeal of the Board’s adverse rulings in the inter partes On February 5, 2020, Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (“Plaintiffs”) brought an action in the United States District Court for the Southern District of New York against the Company and five of its present or former Directors, Dr. Elazar Rabbani, Barry W. Weiner, Dr. Bruce A. Hanna, Dov Perlysky and Rebecca Fischer (“defendants”). On March 26, 2020, Plaintiffs filed an amended complaint against the same defendants. Count I asserted the Company violated Section 14(a) of the Securities and Exchange Act of 1934 and Rule 14a-9 thereunder by disseminating proxy materials that made two purportedly false statements: (a) a “January 28, 2020 Enzo press release [that purportedly] falsely stated that the Annual Meeting would be ‘delayed’ by action of the Board to February 25, 2020 when, in fact, the Annual Meeting would convene as planned on January 31, 2020”, and (b) a “January 31 Enzo Proxy [that purportedly] falsely stated that the Proposed By-Law Amendment [to Article II, Section 9] would be approved if it received…a majority of the votes….rather than the required Supermajority Vote as provided for in the Charter. ”Count II asserted a claim against the individual defendants under Section 20(a) of the Exchange Act premised on Enzo’s purported violation of Section 14(a) and Rule 14a-9. Count III asserted the individual defendants breached their fiduciary duty, based on the same conduct and by seeking to entrench themselves. Finally, Count IV purported to assert a derivative claim for a declaration that any amendment to Article II, Section 2 requires the approval of 80% of Enzo’s shareholders. On July 16, 2020, the day before the defendant’s motion to dismiss was due, plaintiffs asked the Court to dismiss their claims without prejudice. Defendants asked plaintiffs to dismiss the claims with prejudice, but they refused. On July 17, 2020, the Court dismissed the claims without prejudice. If plaintiffs reassert the claims, defendants intend to vigorously defend against them. On November 27, 2020, the Company brought an action in the United States District Court for the Southern District of New York against Harbert Discovery Fund, LP, Harbert Discovery Co-Investment Fund I, LP, Harbert Fund Advisors, Inc., Harbert Management Corp. and Kenan Lucas. The Company alleges the defendants made false and misleading representations, or omitted to state material facts necessary to make their statements not misleading, in proxy materials they disseminated seeking the election to the Company’s Board of Directors at its 2019 Annual Meeting of two candidates they nominated, in violation of Section 14(a) of the 1934 Exchange Act and Rule 14a-9 thereunder. The Company seeks damages and injunctive relief. Defendants have filed a motion to dismiss. The Company has filed its opposition to that motion. There can be no assurance that the Company will be successful in any of these litigations. Even if the Company is not successful, management does not believe that there will be a significant adverse monetary impact on the Company. The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations. As described in Note 3, third-party payers, including government programs, may decide to deny payment or recoup payments for testing that they contend was improperly billed or not medically necessary, against their coverage determinations, or for which they believe they have otherwise overpaid (including as a result of their own error), and we may be required to refund payments already received. During the third fiscal quarter of 2019, a significant third-party payer informed us outside of their typical business practice that they believe it overpaid the Company during certain periods of fiscal 2018. The Company disputed these claims and formally sent legal appeal letters to the payer. During the fiscal 2020 period, we recorded $0.8 million in legal and related expenses as a result of reduced reimbursements this payer made to us. In April 2020, we and the payer entered into a settlement agreement and release whereby the parties agreed that the $0.8 million previously withheld by the payer shall fully and completely satisfy the dispute.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jan. 31, 2021
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. The extent to which the COVID-19 pandemic impacts the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the COVID-19 pandemic, the extent to which it will impact worldwide macroeconomic conditions including, but not limited to, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of January 31, 2021 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s patient self-pay revenue concessions and credit losses in the Clinical Services segment, accounts receivable, inventories and the carrying value of goodwill and other long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods.
Effect of New Accounting Pronouncements	Effect of New Accounting Pronouncements Pronouncements Issued but Not Yet Adopted In June 2016, FASB issued ASU No. 2016-13 Financial Instruments – Credit Losses (Topic 326) In December 2019, the FASB issued ASU No. 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. We reviewed all other recently issued accounting pronouncements and have concluded they are not applicable or not expected to be significant to the accounting for our operations.
Concentration Risk	Concentration Risk Other than the Medicare program, two providers whose programs are included in the “Third-party payers” and “Health Maintenance Organizations” (“HMO’s”) categories represent approximately 35% and 34% of Clinical Services net revenue for the three and six month periods ended January 31, 2021. These two providers represent approximately 33% of Clinical Services net revenue for each of the three and six month periods ended January 31, 2020
Income Taxes	Income Taxes The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance where it is not more likely than not the benefits will be realized in the foreseeable future. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. It is the Company’s policy to provide for uncertain tax positions, if any, and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. To the extent the Company prevails in matters for which a liability for an unrecognized tax benefit is established or is required to pay amounts in excess of the liability, the Company’s effective tax rate in a given financial statement period may be affected. We maintain a full valuation allowance on all tax assets and, as a consequence, do not provide any tax benefit for the fiscal 2020 period loss or tax provision for the fiscal 2021 period pre-tax income.
Fair Value Measurements	Fair Value Measurements The Company determines fair value measurements used in its consolidated financial statements based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs, as determined by either the principal market or the most advantageous market. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy. The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest. Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level 3: Valuations derived from valuation techniques in which one or more significant inputs are unobservable.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jan. 31, 2021
Revenue from Contract with Customer [Abstract]
Schedule of segment revenue and revenue percentage	Three months ended Three months ended Revenue category Third-party payer $ 15,023 63 % $ 6,404 51 % Medicare 3,910 16 3,025 24 Patient self-pay 1,997 8 1,447 12 HMO’s 3,058 13 1,637 13 Total $ 23,988 100 % $ 12,513 100 % Six months ended Six months ended Revenue category Third-party payer $ 27,503 61 % $ 12,796 51 % Medicare 7,313 16 6,178 24 Patient self-pay 4,556 10 2,966 12 HMO’s 5,839 13 3,353 13 Total $ 45,211 100 % $ 25,293 100 %
Schedule of product revenue by geographical	Products revenue by geography is as follows: Three Months Ended January 31 Six Months Ended January 31 2021 2020 2021 2020 United States $ 3,524 $ 3,807 $ 7,469 $ 8,331 Europe 2,635 2,066 5,066 3,975 Asia Pacific 1,319 998 2,375 1,992 Products revenue $ 7,478 $ 6,871 $ 14,910 $ 14,298

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jan. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Inventories	January 31, July 31, Raw materials $ 1,266 $ 1,019 Work in process 2,561 2,587 Finished products 5,431 4,178 $ 9,258 $ 7,784

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	6 Months Ended
	Jan. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Indefinite-Lived Intangible Assets	Gross Accumulated Amortization Net July 31, 2020 $ 27,686 $ (27,148 ) $ 538 Amortization expense - (151 ) (151 ) Foreign currency translation 168 (162 ) 6 January 31, 2021 $ 27,854 $ (27,461 ) $ 393
Schedule of Intangible Assets	January 31, 2021 July 31, 2020 Gross Accumulated Net Gross Accumulated Net Patents $ 11,027 $ (11,023 ) $ 4 $ 11,027 (11,014 ) $ 13 Customer relationships 12,095 (11,706 ) 389 12,003 (11,478 ) 525 Website and acquired content 1,028 (1,028 ) - 1,022 (1,022 ) - Licensed technology and other 492 (492 ) - 483 (483 ) - Trademarks 3,212 (3,212 ) - 3,151 (3,151 ) - Total $ 27,854 $ (27,461 ) $ 393 $ 27,686 (27,148 ) $ 538
Schedule of Useful Lives For Acquisitions	At January 31, 2021, information with respect to acquired intangibles is as follows: Useful life assigned Weighted average Customer relationships 8 -15 years 1 year

Long term debt (Tables)

Long term debt (Tables)	6 Months Ended
	Jan. 31, 2021
Debt Disclosure [Abstract]
Schedule of minimum future annual principal payments	July 31, Total 2021 $ 7,074 2022 152 2023 160 2024 167 2025 604 Thereafter 3,476 Total principal payments 11,633 Less: current portion, included in other current liabilities and other short term debt (7,148 ) Unamortized mortgage cost (57 ) Long term debt - net $ 4,428

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jan. 31, 2021
Leases Disclosure [Abstract]
Schedule of components lease	Leases Balance Sheet Classification January 31, 2021 Assets Operating Right-of-use assets $ 18,459 Finance Property, plant and equipment, net (a) 286 Total lease assets $ 18,745 Liabilities Current: Operating Current portion of operating lease liabilities $ 3,680 Finance Finance leases short term 66 Non-current: Operating Operating lease liabilities, non-current 15,710 Finance Other liabilities and finance leases long term 155 Total lease liabilities $ 19,611 (a) Accumulated amortization of finance lease assets was approximately $1.1 million as of January 31, 2021.
Schedule of lease cost	Three months ended Six months ended 2021 2020 2021 2020 Operating lease cost $ 1,515 $ 1,474 $ 2,994 $ 2,948 Finance lease cost: Amortization of leased assets 33 60 99 115 Interest on lease liabilities 4 22 9 34 Total lease cost $ 1,552 $ 1,556 $ 3,102 $ 3,097
Schedule of lease liability maturity	Maturity of lease liabilities, years ending July 31, Operating leases Finance leases Total 2021 $ 2,436 $ 44 $ 2,480 2022 4,017 88 4,105 2023 3,318 88 3,406 2024 3,173 22 3,195 2025 3,145 — 3,145 Thereafter 6,370 — 6,370 Total lease payments 22,459 242 22,701 Less: Interest (a) (3,069 ) (21 ) (3,090 ) Present value of lease liabilities $ 19,390 $ 221 $ 19,611 (a) Primarily calculated using the Company’s incremental borrowing rate.
Schedule of lease term and discount rate	Lease term and discount rate Weighted-average remaining lease term (years): Operating leases 5.9 years Finance leases 2.9 years Weighted-average discount rate: Operating leases 4.95 % Finance leases 9.02 %

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jan. 31, 2021
Payables and Accruals [Abstract]
Schedule of accrued liabilities	January 31, July 31, Payroll, benefits, and commissions $ 5,601 $ 5,227 Professional fees 704 710 Legal 3,638 2,647 Deferred revenue – CARES Act Advance Payment 2,526 2,526 Other 2,120 1,723 $ 14,589 $ 12,833

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jan. 31, 2021
Stockholders' Equity Note [Abstract]
Schedule of amounts of share-based compensation expense	Three months ended Six months ended 2021 2020 2021 2020 Stock options $ 175 $ 301 $ 341 $ 518 Restricted stock 1 1 2 3 $ 176 $ 302 $ 343 $ 521
Schedule of share-based payment arrangement	Three months ended Six months ended 2021 2020 2021 2020 Selling, general and administrative $ 162 $ 302 $ 316 $ 521 Cost of revenues 14 - 27 - $ 176 $ 302 $ 343 $ 521
Schedule of stock option activity	Options Weighted Weighted Aggregate Outstanding at July 31, 2020 2,636,496 $ 4.05 Awarded 543,104 $ 2.57 Exercised — $ Expired or forfeited (408,539 ) $ 2.91 Outstanding at end of period 2,771,061 $ 3.80 3.0 years $ 114 Exercisable at end of period 1,566,259 $ 1.9 years $
Schedule of nonvested performance-based units activity	Grant Date Total Grant Forfeitures Outstanding Fair Market Value At Grant Date (000s) 10/15/2018 32,000 (6,000 ) 26,000 $ 107 10/15/2019 80,500 (14,500 ) 66,000 $ 222 10/19/2020 98,600 - 98,600 $ 207

Segment reporting (Tables)

Segment reporting (Tables)	6 Months Ended
	Jan. 31, 2021
Segment Reporting [Abstract]
Schedule of financial information represents the operating results of the reportable segments	Three months ended January 31, 2021 Clinical Products Therapeutics Other Consolidated Revenues – Services and Products $ 23,988 $ 7,478 - - $ 31,466 Operating costs and expenses: Cost of revenues 11,708 3,937 - - 15,645 Research and development 160 633 $ 13 - 806 Selling, general and administrative 6,425 2,593 16 $ 1,979 11,013 Legal and related expenses 71 1 - 2,220 2,292 Total operating costs and expenses 18,364 7,164 29 4,199 29,756 Operating income (loss) 5,624 314 (29 ) (4,199 ) 1,710 Other income (expense): Interest (4 ) 8 - (53 ) (49 ) Other 14 2 - - 16 Foreign exchange gain - 625 - - 625 Net income (loss) $ 5,634 $ 949 $ (29 ) $ (4,252 ) $ 2,302 Depreciation and amortization included above $ 381 $ 188 $ - $ 66 $ 635 Share-based compensation included in above: Selling, general and administrative 10 16 - 136 162 Cost of revenues 14 - - - 14 Total $ 24 $ 16 $ - $ 136 $ 176 Capital expenditures $ 341 $ 154 $ - $ 11 $ 506 Three months ended January 31, 2020 Clinical Products Therapeutics Other Consolidated Revenues $ 12,513 $ 6,871 - - $ 19,384 Operating costs and expenses: Cost of revenues 10,243 3,332 - - 13,575 Research and development 373 503 189 - 1,065 Selling, general and administrative 5,895 2,530 - 2,268 10,693 Legal fee expense 38 1 - 2,021 2,060 Total operating costs and expenses 16,549 6,366 189 4,289 27,393 Operating income (loss) (4,036 ) 505 (189 ) (4,289 ) (8,009 ) Other income (expense): Interest (10 ) 16 - 165 171 Other 16 7 - 49 72 Foreign exchange gain - 79 - - 79 Net (loss) income $ (4,030 ) 607 (189 ) (4,075 ) (7,687 ) Depreciation and amortization included above $ 392 253 - 65 710 Share-based compensation included in above: Selling, general and administrative 33 22 - 247 302 Total $ 33 22 - 247 302 Capital expenditures $ 142 18 - - 160 Six months ended January 31, 2021 Clinical Products Therapeutics Other Consolidated Revenues – Services and Products $ 45,211 $ 14,910 - - $ 60,121 Operating costs and expenses: Cost of revenues 24,703 7,700 - - 32,403 Research and development 281 1,225 $ 46 - 1,552 Selling, general and administrative 12,523 5,038 33 $ 3,433 21,027 Legal and related expenses 96 6 - 2,830 2,932 Total operating costs and expenses 37,603 13,969 79 6,263 57,914 Operating income (loss) 7,608 941 (79 ) (6,263 ) 2,207 Other income (expense): Interest (10 ) 18 - (108 ) (100 ) Other 29 4 - - 33 Foreign exchange gain 461 - - 461 Net income (loss) $ 7,627 $ 1,424 $ (79 ) $ (6,371 ) $ 2,601 Depreciation and amortization included above $ 790 $ 373 $ - $ 132 $ 1,295 Share-based compensation included in above: Selling, general and administrative 19 32 - 265 316 Cost of revenues 27 - - - 27 Total $ 46 $ 32 $ - $ 265 $ 343 Capital expenditures $ 881 $ 198 $ - $ 44 $ 1,123 Six months ended January 31, 2020 Clinical Products Therapeutics Other Consolidated Revenues – Services and Products $ 25,293 $ 14,298 - - $ 39,591 Operating costs and expenses: Cost of revenues 21,218 6,878 - - 28,096 Research and development 723 1,019 $ 377 - 2,119 Selling, general and administrative 12,110 5,287 - $ 4,435 21,832 Legal and related expenses 88 1 - 3,667 3,756 Total operating costs and expenses 34,139 13,185 377 8,102 55,803 Operating income (loss) (8,846 ) 1,113 (377 ) (8,102 ) (16,212 ) Other income (expense): Interest (22 ) 34 - 396 408 Other 19 (5 ) - 185 199 Foreign exchange gain - 270 - - 270 Net income (loss) $ (8,849 ) $ 1,412 $ (377 ) $ (7,521 ) $ (15,335 ) Depreciation and amortization included above $ 801 $ 503 $ - $ 130 $ 1,434 Share-based compensation included in above: Selling, general and administrative. 67 44 - 410 521 Total $ 67 $ 44 $ - $ 410 $ 521 Capital expenditures $ 289 $ 145 $ - $ - $ 434

Basis of Presentation (Details)

Basis of Presentation (Details)	3 Months Ended		6 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2021	Jan. 31, 2020
Clinical Services [Member] | Third-party payers” and “Health Maintenance Organizations [Member] | Revenue Benchmark [Member]
Basis of Presentation (Details) [Line Items]
Concentration risk, percentage	35.00%	33.00%	34.00%	33.00%

Net income (loss) per share (De

Net income (loss) per share (Details) - shares	3 Months Ended		6 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2021	Jan. 31, 2020
Net income (loss) per share (Details) [Line Items]
Weighted average stock options of diluted weighted average shares outstanding	47,000		23,000
Unvested Restricted Stock [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		0		64,000
Out of the money options [Member]
Net income (loss) per share (Details) [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	2,264,000	1,897,000	2,122,000	1,606,000

Revenue Recognition (Details)

Revenue Recognition (Details)	6 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Government Payer - Medicare [Member]
Revenue Recognition (Details) [Line Items]
Billing information filing deadline period	60 days
Patient Selfpay [Member]
Revenue Recognition (Details) [Line Items]
Billing period	91 days
Receivable collection period	105 days
Products Revenue [Member]
Revenue Recognition (Details) [Line Items]
Claim period for return of goods	30 days
Minimum [Member] | Third Party Payer And Health Maintenance Organizations [Member]
Revenue Recognition (Details) [Line Items]
Billing information filing deadline period	30 days
Minimum [Member] | Products Revenue [Member]
Revenue Recognition (Details) [Line Items]
Receivable collection period	30 days
Maximum [Member] | Third Party Payer And Health Maintenance Organizations [Member]
Revenue Recognition (Details) [Line Items]
Billing information filing deadline period	90 days
Maximum [Member] | Products Revenue [Member]
Revenue Recognition (Details) [Line Items]
Receivable collection period	90 days
Clinical Services [Member]
Revenue Recognition (Details) [Line Items]
Concentration risk, percentage	75.00%	64.00%

Revenue Recognition (Details) -

Revenue Recognition (Details) - Schedule of segment revenue and revenue percentage - Clinical Services [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2021	Jan. 31, 2020
Revenue Recognition (Details) - Schedule of segment revenue and revenue percentage [Line Items]
Revenue services net	$ 23,988	$ 12,513	$ 45,211	$ 25,293
Revenue services net, percentage	100.00%	100.00%	100.00%	100.00%
Third party payers [Member]
Revenue Recognition (Details) - Schedule of segment revenue and revenue percentage [Line Items]
Revenue services net	$ 15,023	$ 6,404	$ 27,503	$ 12,796
Revenue services net, percentage	63.00%	51.00%	61.00%	51.00%
Medicare [Member]
Revenue Recognition (Details) - Schedule of segment revenue and revenue percentage [Line Items]
Revenue services net	$ 3,910	$ 3,025	$ 7,313	$ 6,178
Revenue services net, percentage	16.00%	24.00%	16.00%	24.00%
Patient Selfpay [Member]
Revenue Recognition (Details) - Schedule of segment revenue and revenue percentage [Line Items]
Revenue services net	$ 1,997	$ 1,447	$ 4,556	$ 2,966
Revenue services net, percentage	8.00%	12.00%	10.00%	12.00%
621491 HMO Medical Centers [Member]
Revenue Recognition (Details) - Schedule of segment revenue and revenue percentage [Line Items]
Revenue services net	$ 3,058	$ 1,637	$ 5,839	$ 3,353
Revenue services net, percentage	13.00%	13.00%	13.00%	13.00%

Revenue Recognition (Details)_2

Revenue Recognition (Details) - Schedule of Product revenue by geographical - Product Revenue [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2021	Jan. 31, 2020
Revenue Recognition (Details) - Schedule of Product revenue by geographical [Line Items]
Products revenue	$ 7,478	$ 6,871	$ 14,910	$ 14,298
United States [Member]
Revenue Recognition (Details) - Schedule of Product revenue by geographical [Line Items]
Products revenue	3,524	3,807	7,469	8,331
Europe [Member]
Revenue Recognition (Details) - Schedule of Product revenue by geographical [Line Items]
Products revenue	2,635	2,066	5,066	3,975
Asia Pacific [Member]
Revenue Recognition (Details) - Schedule of Product revenue by geographical [Line Items]
Products revenue	$ 1,319	$ 998	$ 2,375	$ 1,992

Supplemental Disclosure for S_2

Supplemental Disclosure for Statement of Cash Flows (Details) - USD ($) $ in Thousands	6 Months Ended
	Jan. 31, 2021	Jan. 31, 2020
Supplemental Cash Flow Elements [Abstract]
Interest paid	$ 123	$ 136
Reductions in measurement right of use assets and liabilities	$ 48	$ 91
Common stock to executives (in Shares)	332,700
Accrued bonuses	$ 875

Inventories (Details) - Schedul

Inventories (Details) - Schedule of Inventories - USD ($) $ in Thousands	Jan. 31, 2021	Jul. 31, 2020
Schedule of Inventories [Abstract]
Raw materials	$ 1,266	$ 1,019
Work in process	2,561	2,587
Finished products	5,431	4,178
Total inventories	$ 9,258	$ 7,784

Goodwill and intangible asset_2

Goodwill and intangible assets (Details) - USD ($) $ in Thousands	6 Months Ended
	Jan. 31, 2021	Jul. 31, 2020	Jan. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 7,452	$ 7,452	$ 7,452
Weighted average remaining useful life	2 years

Goodwill and intangible asset_3

Goodwill and intangible assets (Details) - Schedule of Indefinite-Lived Intangible Assets $ in Thousands	6 Months Ended
	Jan. 31, 2021USD ($)
Schedule of Indefinite-Lived Intangible Assets [Abstract]
Gross, Beginning Balance	$ 27,686
Accumulated Amortization, Beginning Balance	(27,148)
Net, Beginning Balance	538
Amortization expense, Gross
Amortization expense, Accumulated Amortization	(151)
Amortization expense, Net	(151)
Foreign currency translation, Gross	168
Foreign currency translation, Accumulated Amortization	(162)
Foreign currency translation, Net	6
Gross, Ending Balance	27,854
Accumulated Amortization, Ending Balance	(27,461)
Net, Ending Balance	$ 393

Goodwill and intangible asset_4

Goodwill and intangible assets (Details) - Schedule of Intangible Assets - USD ($) $ in Thousands	Jan. 31, 2021	Jul. 31, 2020
Goodwill and intangible assets (Details) - Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	$ 27,854	$ 27,686
Finite-lived intangible assets, Accumulated Amortization	(27,461)	(27,148)
Finite-lived intangible assets, Net	393	538
Patents [Member]
Goodwill and intangible assets (Details) - Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	11,027	11,027
Finite-lived intangible assets, Accumulated Amortization	(11,023)	(11,014)
Finite-lived intangible assets, Net	4	13
Customer Relationships [Member]
Goodwill and intangible assets (Details) - Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	12,095	12,003
Finite-lived intangible assets, Accumulated Amortization	(11,706)	(11,478)
Finite-lived intangible assets, Net	389	525
Website and Acquired Content [Member]
Goodwill and intangible assets (Details) - Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	1,028	1,022
Finite-lived intangible assets, Accumulated Amortization	(1,028)	(1,022)
Finite-lived intangible assets, Net
Licensed Technology and Other [Member]
Goodwill and intangible assets (Details) - Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	492	483
Finite-lived intangible assets, Accumulated Amortization	(492)	(483)
Finite-lived intangible assets, Net
Trademarks [Member]
Goodwill and intangible assets (Details) - Schedule of Intangible Assets [Line Items]
Finite-lived intangible assets, Gross	3,212	3,151
Finite-lived intangible assets, Accumulated Amortization	(3,212)	(3,151)
Finite-lived intangible assets, Net

Goodwill and intangible asset_5

Goodwill and intangible assets (Details) - Schedule of Useful Lives For Acquisitions - Customer Relationships [Member]	6 Months Ended
	Jan. 31, 2021
Goodwill and intangible assets (Details) - Schedule of Useful Lives For Acquisitions [Line Items]
Weighted average remaining useful life	1 year
Minimum [Member]
Goodwill and intangible assets (Details) - Schedule of Useful Lives For Acquisitions [Line Items]
Useful life assigned	8 years
Maximum [Member]
Goodwill and intangible assets (Details) - Schedule of Useful Lives For Acquisitions [Line Items]
Useful life assigned	15 years

Long term debt (Details)

Long term debt (Details) $ in Thousands, SFr in Millions	1 Months Ended			6 Months Ended
	Jan. 31, 2021USD ($)	Apr. 30, 2020CHF (SFr)	Nov. 30, 2018USD ($)	Jan. 31, 2021USD ($)	Apr. 30, 2020USD ($)
Long term debt (Details) [Line Items]
Debt instrument, face amount			$ 4,500
Debt instrument maturity period			10 years
Debt instrument, interest rate, stated percentage			5.09%
Debt instrument, periodic payment			$ 30
Amortization of debt issuance costs			$ 72
Unamortized debt issuance expense	$ 57			$ 57
Mortgage agreement	4,200			4,200
Cash collateral for borrowed securities	750			$ 750
Operating lease, description				We assumed from the seller an operating lease for a tenant at the facility which expired on June 30, 2020.
Liquid assets	25,000			$ 25,000
Foreign exchange rate amount	$ 400	SFr 0.4
Bear interest rate	0.00%			0.00%
Long term debt term	5 years			5 years
Fixed interest rate, description				PPP loans have a 1% fixed interest rate and are due from two to five years.
Maturity date, description				The PPP Loan matures on April 17, 2022 (the “Maturity Date”), accrues interest at 1% per annum and may be prepaid in whole or in part without penalty.
Intention to audit loans in excess	$ 2,000			$ 2,000
Excess loans	$ 2,000			$ 2,000
Citibank N.A [Member]
Long term debt (Details) [Line Items]
Cash collateral for borrowed securities					$ 7,000

Long term debt (Details) - Sche

Long term debt (Details) - Schedule of minimum future annual principal payments - USD ($) $ in Thousands	Jan. 31, 2021	Jul. 31, 2020
Schedule of minimum future annual principal payments [Abstract]
2021	$ 7,074
2022	152
2023	160
2024	167
2025	604
Thereafter	3,476
Total principal payments	11,633
Less: current portion, included in other current liabilities and other short term debt	(7,148)
Unamortized mortgage cost	(57)
Long term debt - net	$ 4,428	$ 4,485

Leases (Details)

Leases (Details) $ in Millions	6 Months Ended
	Jan. 31, 2021USD ($)
Leases (Details) [Line Items]
Lease option maximum extension period	5 years
Accumulated amortization of finance lease assets (in Dollars)	$ 1.1
Minimum [Member]
Leases (Details) [Line Items]
Lease term of contract	1 year
Maximum [Member]
Leases (Details) [Line Items]
Lease term of contract	8 years

Leases (Details) - Schedule of

Leases (Details) - Schedule of components lease - USD ($) $ in Thousands		Jan. 31, 2021	Jul. 31, 2020
Assets
Operating, Right-of-use assets		$ 18,459	$ 19,916
Finance, Property, plant and equipment, net	[1]	286
Total lease assets		18,745
Current:
Operating, Current portion of operating lease liabilities		3,680	4,121
Finance, Finance leases short term		66
Non-current:
Operating, Operating lease liabilities, non-current		15,710	$ 16,679
Finance, Other liabilities and finance leases long term		155
Total lease liabilities		$ 19,611
[1]	Accumulated amortization of finance lease assets was approximately $1.1 million as of January 31, 2021.

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of lease cost - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2021	Jan. 31, 2020
Schedule of lease cost [Abstract]
Operating lease cost	$ 1,515	$ 1,474	$ 2,994	$ 2,948
Finance lease cost:
Amortization of leased assets	33	60	99	115
Interest on lease liabilities	4	22	9	34
Total lease cost	$ 1,552	$ 1,556	$ 3,102	$ 3,097

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of lease liability maturity $ in Thousands	Jan. 31, 2021USD ($)
Schedule of lease liability maturity [Abstract]
2021, Operating leases	$ 2,436
2021, Finance leases	44
2021, Total	2,480
2022, Operating leases	4,017
2022, Finance leases	88
2022, Total	4,105
2023, Operating leases	3,318
2023, Finance leases	88
2023, Total	3,406
2024, Operating leases4	3,173
2024, Finance leases	22
2024, Total	3,195
2025, Operating leases4	3,145
2025, Finance leases
2025, Total	3,145
Thereafter, Operating leases	6,370
Thereafter, Finance lease
Thereafter, Total	6,370
Total lease payments, Operating leases	22,459
Total lease payments, Finance leases	242
Total lease payments, Total	22,701
Less: Interest, Operating leases	(3,069)	[1]
Less: Interest, Finance leases	(21)	[1]
Less: Interest, Total	(3,090)	[1]
Present value of lease liabilities, Operating leases	19,390
Present value of lease liabilities, Finance leases	221
Present value of lease liabilities, Total	$ 19,611
[1]	Primarily calculated using the Company’s incremental borrowing rate.

Leases (Details) - Schedule o_4

Leases (Details) - Schedule of lease term and discount rate	Jan. 31, 2021
Weighted-average remaining lease term (years):
Weighted-average remaining lease term: Operating leases	5 years 328 days
Weighted-average remaining lease term: Finance leases	2 years 328 days
Weighted-average discount rate:
Weighted-average discount rate: Operating leases	4.95%
Weighted-average discount rate: Finance leases	9.02%

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	1 Months Ended	6 Months Ended
	Apr. 30, 2020	Jan. 31, 2021
Payables and Accruals [Abstract]
Payment advance	$ 2,526
Accrual, real and personal property taxes, uncertainty		25%
Accrued liabilities and other liabilities		$ 349

Accrued Liabilities (Details) -

Accrued Liabilities (Details) - Schedule of accrued liabilities - USD ($) $ in Thousands	Jan. 31, 2021	Jul. 31, 2020
Schedule of accrued liabilities [Abstract]
Payroll, benefits, and commissions	$ 5,601	$ 5,227
Professional fees	704	710
Legal	3,638	2,647
Deferred revenue – CARES Act Advance Payment	2,526	2,526
Other	2,120	1,723
Accrued liabilities	$ 14,589	$ 12,833

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		6 Months Ended
	Jan. 05, 2018	Sep. 30, 2017	Jan. 31, 2021	Jan. 31, 2020	Jul. 31, 2020	Dec. 31, 2014	Jan. 31, 2011
Stockholders' Equity (Details) [Line Items]
Common stock, par value (in Dollars per share)			$ 0.01		$ 0.01
Percentage of commission payable on equity offering			3.00%
Maximum offering price under sales agreement			$ 20,000			$ 20,000
Common stock available for grant, description			(i) increasing the shares of common stock available for grant under the Amended and Restated 2011 Plan by an additional 4,000,000 shares of common stock bringing the total number of shares available for grant to 9,000,000 shares of common stock and (ii) extending the term of the Amended and Restated 2011 Plan until October 7, 2030.
Share-based compensation arrangement by share-based payment award, number of shares available for grant (in Shares)			4,623,000
Compensation cost related to non-vested options			$ 1,079
Performance share, description			one former executive forfeited a total of 6,000 PSUs	one former executive forfeited a total of 14,500 PSUs.
2011 Plan [Member]
Stockholders' Equity (Details) [Line Items]
Share based compensation arrangement by share based payment award restricted stock units (in Shares)							3,000,000
Share-based compensation arrangement by share-based payment award, number of additional shares authorized (in Shares)	2,000,000
Common stock available for grants (in Shares)	5,000,000
Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Authorized common stock that may be issued and sold under sales agreement		$ 19,200
Securities that may be sold under the agreement		$ 150,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of amounts of share-based compensation expense - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2021	Jan. 31, 2020
Stockholders' Equity (Details) - Schedule of amounts of share-based compensation expense [Line Items]
Share-based compensation expense	$ 176	$ 302	$ 343	$ 521
Stock options [Member]
Stockholders' Equity (Details) - Schedule of amounts of share-based compensation expense [Line Items]
Share-based compensation expense	175	301	341	518
Restricted stock [Member]
Stockholders' Equity (Details) - Schedule of amounts of share-based compensation expense [Line Items]
Share-based compensation expense	$ 1	$ 1	$ 2	$ 3

Stockholders' Equity (Details_2

Stockholders' Equity (Details) - Schedule of share-based payment arrangement - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2021	Jan. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payment arrangement	$ 176	$ 302	$ 343	$ 521
Selling, general and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payment arrangement	162	302	316	521
Cost of revenues [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based payment arrangement	$ 14		$ 27

Stockholders' Equity (Details_3

Stockholders' Equity (Details) - Schedule of stock option activity $ / shares in Units, $ in Thousands	6 Months Ended
	Jan. 31, 2021USD ($)$ / sharesshares
Schedule of stock option activity [Abstract]
Outstanding beginning, Options	2,636,496
Outstanding beginning, Weighted Average Exercise Price (in Dollars per share) | $ / shares	$ 4.05
Awarded, Options	543,104
Awarded, Weighted Average Exercise Price (in Dollars per share) | $ / shares	$ 2.57
Exercised, Options
Cancelled or expired, Options	(408,539)
Cancelled or expired, Weighted Average Exercise Price (in Dollars per share) | $ / shares	$ 2.91
Outstanding at end of period, Options	2,771,061
Outstanding at end of period, Weighted Average Exercise Price (in Dollars per share) | $ / shares	$ 3.80
Outstanding at end of period, Weighted Average Remaining Contractual Term	3 years
Outstanding at end of period, Aggregate Intrinsic Value (in Dollars) | $	$ 114
Exercisable at end of period, Options	1,566,259
Exercisable at end of period, Weighted Average Remaining Contractual Term	1 year 328 days

Stockholders' Equity (Details_4

Stockholders' Equity (Details) - Schedule of nonvested performance-based units activity - Executive Officer [Member] - USD ($) $ in Thousands	Oct. 15, 2019	Oct. 15, 2018	Oct. 19, 2020
Performance share 1 [Member]
Stockholders' Equity (Details) - Schedule of nonvested performance-based units activity [Line Items]
Total Grant		32,000
Forfeitures		(6,000)
Outstanding		26,000
Fair Market Value At Grant Date (in Dollars)		$ 107
Performance share 2 [Member]
Stockholders' Equity (Details) - Schedule of nonvested performance-based units activity [Line Items]
Total Grant	80,500
Forfeitures	(14,500)
Outstanding	66,000
Fair Market Value At Grant Date (in Dollars)	$ 222
Performance share 3 [Member]
Stockholders' Equity (Details) - Schedule of nonvested performance-based units activity [Line Items]
Total Grant			98,600
Forfeitures
Outstanding			98,600
Fair Market Value At Grant Date (in Dollars)			$ 207

Segment reporting (Details)

Segment reporting (Details)	6 Months Ended
	Jan. 31, 2021
Segment Reporting [Abstract]
Number of reportable segments	3

Segment reporting (Details) - S

Segment reporting (Details) - Schedule of financial information represents the operating results of the reportable segments - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2021	Jan. 31, 2020
Clinical Services [Member]
Segment Reporting Information [Line Items]
Revenues – Services and Products	$ 23,988	$ 12,513	$ 45,211	$ 25,293
Operating costs and expenses:
Cost of revenues	11,708	10,243	24,703	21,218
Capital expenditures	341	142	881	289
Research and development	160	373	281	723
Selling, general and administrative	6,425	5,895	12,523	12,110
Legal and related expenses	71	38	96	88
Total operating costs and expenses	18,364	16,549	37,603	34,139
Operating income (loss)	5,624	(4,036)	7,608	(8,846)
Other income (expense):
Interest	(4)	(10)	(10)	(22)
Other	14	16	29	19
Foreign exchange loss
Net income (loss)	5,634	(4,030)	7,627	(8,849)
Depreciation and amortization included above	381	392	790	801
Products [Member]
Segment Reporting Information [Line Items]
Revenues – Services and Products	7,478	6,871	14,910	14,298
Operating costs and expenses:
Cost of revenues	3,937	3,332	7,700	6,878
Capital expenditures	154	18	198	145
Research and development	633	503	1,225	1,019
Selling, general and administrative	2,593	2,530	5,038	5,287
Legal and related expenses	1	1	6	1
Total operating costs and expenses	7,164	6,366	13,969	13,185
Operating income (loss)	314	505	941	1,113
Other income (expense):
Interest	8	16	18	34
Other	2	7	4	(5)
Foreign exchange loss	625	79	461	270
Net income (loss)	949	607	1,424	1,412
Depreciation and amortization included above	188	253	373	503
Therapeutics [Member]
Segment Reporting Information [Line Items]
Revenues – Services and Products
Operating costs and expenses:
Cost of revenues
Capital expenditures
Research and development	13	189	46	377
Selling, general and administrative	16		33
Legal and related expenses
Total operating costs and expenses	29	189	79	377
Operating income (loss)	(29)	(189)	(79)	(377)
Other income (expense):
Interest
Other
Foreign exchange loss
Net income (loss)	(29)	(189)	(79)	(377)
Depreciation and amortization included above
Other [Member]
Segment Reporting Information [Line Items]
Revenues – Services and Products
Operating costs and expenses:
Cost of revenues
Capital expenditures	11		44
Research and development
Selling, general and administrative	1,979	2,268	3,433	4,435
Legal and related expenses	2,220	2,021	2,830	3,667
Total operating costs and expenses	4,199	4,289	6,263	8,102
Operating income (loss)	(4,199)	(4,289)	(6,263)	(8,102)
Other income (expense):
Interest	(53)	165	(108)	396
Other		49		185
Foreign exchange loss
Net income (loss)	(4,252)	(4,075)	(6,371)	(7,521)
Depreciation and amortization included above	66	65	132	130
Consolidated [Member]
Segment Reporting Information [Line Items]
Revenues – Services and Products	31,466	19,384	60,121	39,591
Operating costs and expenses:
Cost of revenues	15,645	13,575	32,403	28,096
Capital expenditures	506	160	1,123	434
Research and development	806	1,065	1,552	2,119
Selling, general and administrative	11,013	10,693	21,027	21,832
Legal and related expenses	2,292	2,060	2,932	3,756
Total operating costs and expenses	29,756	27,393	57,914	55,803
Operating income (loss)	1,710	(8,009)	2,207	(16,212)
Other income (expense):
Interest	(49)	171	(100)	408
Other	16	72	33	199
Foreign exchange loss	625	79	461	270
Net income (loss)	2,302	(7,687)	2,601	(15,335)
Depreciation and amortization included above	635	710	1,295	1,434
Selling, General and Administrative Expenses [Member] | Clinical Services [Member]
Operating costs and expenses:
Selling, general and administrative	10	33	19	67
Selling, General and Administrative Expenses [Member] | Products [Member]
Operating costs and expenses:
Selling, general and administrative	16	22	32	44
Selling, General and Administrative Expenses [Member] | Therapeutics [Member]
Operating costs and expenses:
Selling, general and administrative
Selling, General and Administrative Expenses [Member] | Other [Member]
Operating costs and expenses:
Selling, general and administrative	136	247	265	410
Selling, General and Administrative Expenses [Member] | Consolidated [Member]
Operating costs and expenses:
Selling, general and administrative	162	302	316	521
Cost of Revenues [Member] | Clinical Services [Member]
Operating costs and expenses:
Cost of revenues	14		27
Cost of Revenues [Member] | Products [Member]
Operating costs and expenses:
Cost of revenues
Cost of Revenues [Member] | Therapeutics [Member]
Operating costs and expenses:
Cost of revenues
Cost of Revenues [Member] | Other [Member]
Operating costs and expenses:
Cost of revenues
Cost of Revenues [Member] | Consolidated [Member]
Operating costs and expenses:
Cost of revenues	14		27
Total [Member] | Clinical Services [Member]
Operating costs and expenses:
Total	24	33	46	67
Total [Member] | Products [Member]
Operating costs and expenses:
Total	16	22	32	44
Total [Member] | Therapeutics [Member]
Operating costs and expenses:
Total
Total [Member] | Other [Member]
Operating costs and expenses:
Total	136	247	265	410
Total [Member] | Consolidated [Member]
Operating costs and expenses:
Total	$ 176	$ 302	$ 343	$ 521

Contingencies (Details)

Contingencies (Details) - USD ($) $ in Millions	1 Months Ended	6 Months Ended	12 Months Ended
	Apr. 30, 2020	Jan. 31, 2021	Jul. 31, 2020
Loss Contingency [Abstract]
Contingencies approval, percent		80.00%
Legal and related expenses			$ 0.8
Litigation settlement, amount awarded from other party	$ 0.8